Stocktoria
Evolus, Inc. EOLS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-02-08
Evolus, Inc. statistics & valuation
Market cap$469.5M
P / S1.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 66.3% | 68.5% | 68.1% | 60.4% | — |
| Operating margin | -11.0% | -12.9% | -24.4% | -44.0% | -44.6% |
| Net margin | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% |
| FCF margin | -15.4% | -7.3% | -17.1% | -58.2% | -33.9% |
| Return on assets | -22.9% | -21.7% | -32.6% | -41.8% | -18.2% |
| Return on equity | 223.5% | -913.1% | 298.2% | -402.2% | -57.2% |
| Debt / equity | -6.32× | 22.00× | -5.82× | 3.89× | 0.87× |
| Current ratio | 1.90 | 2.40 | 2.33 | 2.17 | 3.10 |
| Revenue growth | 11.6% | 31.8% | 36.0% | 49.1% | 76.3% |
Source: SEC EDGAR filings · CIK 0001570562 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.